Cagrilintide

Fat LossInvestigational amylin analogEmerging

Long-acting amylin analog from Novo Nordisk in Phase 3 obesity programs, including the CagriSema combination with semaglutide. Not FDA-approved as of 2026.

Calculate Dose

For research use only.

Key Facts

CAS: 1415456-99-3
Molecular Weight (MW): ~4749 g/mol
Half-life: ~6–7 days
Unit: mg
Administration Route: Subcutaneous
Frequency: Once weekly (trial programs)
Last updated: 8/23/2026
Targets: Amylin receptorCalcitonin receptor

Overview

Long-acting amylin analog from Novo Nordisk in Phase 3 obesity programs, including the CagriSema combination with semaglutide. Not FDA-approved as of 2026.

Protocol

Dosage Range: Weekly titration in trials (often 0.3–2.4 mg class range)
Frequency: Once weekly (trial programs)
Cycle: Long-term obesity trial setting
Administration Route: Subcutaneous
Reconstitution Guide: 2 mL BAC water for 5 mg vial

Science

Mechanism of Action

Acylated amylin analog that activates amylin (and calcitonin) receptors to reduce food intake and slow gastric emptying, complementary to GLP-1 agonism.